genedrive plc
("genedrive" or the "Company")
Total Voting Rights
genedrive plc (AIM:GDR), the point of care molecular diagnostics company, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 6 April 2023 the Company's issued share capital consists of 99,049,946 Ordinary Shares of 1.5p each. This follows the Admission today of 6,500,000 Ordinary Shares of 1.5p each further to the Company's announcement on 31 March 2023 including details of a £5m Equity Prepayment Facility.
The total number of voting rights in the Company is 99,049,946 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further details please contact:
genedrive plc | +44 (0)161 989 0245 |
David Budd: CEO / Russ Shaw: CFO | |
| |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)20 7418 8900 |
James Steel / Oliver Duckworth | |
| |
finnCap (Joint Broker) | +44 (0)20 7220 0500 |
Geoff Nash / Alice Lane | |
| |
Walbrook PR Ltd (Media & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 |
About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The company are currently developing a genetic test for CYP2C19 metaboliser status.
The Genedrive® MT-RNR1 ID Kit, selected as 1 of the 10 EVA pilot projects, is the world's first commercial point-of-care genetic test for emergency care. It helps to avoid irreversible lifelong hearing loss in specific infants exposed to aminoglycosides by rapidly detecting the m.1555A>G gene variant that can cause lifelong deafness, allowing for alternative antibiotics to be prescribed. Product information can be found at https://www.genedrive.com/assays/rnr1-product.php
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.